[1]Kapiteijn E,Marijnen CA,Colenbrander AC,et al. Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: a population-based study in the west Netherlands. Eur J Surg Oncol,1998,24:528-535. [2]Kapiteijn E,Putter H,van de Velde CJ,et al. Cooperative Investigators of the Dutch Colorectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg,2002,89:1142-1149. [3]Cammà C,Giunta M,Fiorica F,et al. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA,2000,284:1008-1115. [4]Ceelen WP,Van Nieuwenhove Y,Fierens K. Preoperative chemoradiation versus radiation alone for stage Ⅱ and Ⅲ resectable rectal cancer. Cochrane Database Syst Rev,2009:CD006041. [5]Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med,2004,351:1731-1740. [6]Roh MS,Colangelo LH,O′Connell MJ,et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol,2009,27:5124-5130. [7]Park IJ,Kim HC,Yu CS,et al. Effect of adjuvant radiotherapy on local recurrence in stage Ⅱ rectal cancer. Ann Surg Oncol,2008,15:519-525. [8]Willett CG,Badizadegan K,Ancukiewicz M,et al. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum,1999,42:167-173. [9]Merchant NB,Guillem JG,Paty PB,et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg,1999,3:642-647. [10]Kim JS,Kim NK,Min BS,et al.Adjuvant radiotherapy following total mesorectal excision for stage ⅡA rectal cancer:is it beneficial? Int J Colorectal Dis,2010,25:1103-1110. [11]Sebag-Montefiore D,Stephens RJ,Steele R,et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer(MRC CR07 and NCIC-CTG C016):a multicentre,randomised trial. Lancet,2009,373:811-820. [12]Guillem JG,Diaz-Gonzalez JA,Minsky BD,et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol,2008,26:368-373. [13]Lombardi R,Cuicchi D,Pinto C,et al. Clinically staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? Ann Surg Oncol,2010,17:838-845. [14]Folkesson J,Birgisson H,Pahlman L,et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol,2005,23:5644-5650. [15]Kapiteijn E,Marijnen CA,Nagtegaal ID,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med,2001,345:638-646. [16]Pilipshen SJ,Heilweil M,Quan SH,et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer,1984,53:1354-1362. [17]Nelson H,Petrelli N,Carlin A,et al. Guidelines in 2000 for colon and rectal cancer surgery. J Natl Cancer Inst,2001,93:583-596. [18]Viani GA,Stefano EJ,Soares FV,et al. Evaluation of biologic effective dose and schedule of fractionation for preoperative radiotherapy for rectal cancer: meta-analyses and meta-regression. Int J Radiat Oncol Biol Phys,2011,80:985-991. [19]Wiltshire KL,Ward IG,Swallow C,et al. Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response,local recurrence-free survival,disease-free survival,and overall survival. Int J Radiat Oncol Biol Phys,2006,64:709-716. [20]Mohiuddin M,Regine WF,John WJ,et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys,2000,46:883-888. [21]Van Gijn W,Marijnen CA,Nagtegaal ID,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre,randomised controlled TME trial. Lancet Oncol,2011,12:575-582. [22]Gérard JP,Conroy T,Bonnetain F,et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol,2006,24:4620-4625. [23]Bujko K,Nowacki MP,Nasierowska-Guttmejer A,et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol,2004,72:15-24. [24]Bujko K,Nowacki MP,Nasierowska-Guttmejer A,et al. Long term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg,2006,93:1215-1223. [25]Pettersson D,Cedermark B,Holm T,et al. Interim analysis of the Stockholm Ⅲ trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg,2010,97:580-587. [26]Ballonoff A,Kavanagh B,McCarter M,et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase Ⅱ trial. Am J Clin Oncol,2008,31:264-270. [27]Li JL,Ji JF,Cai Y,et al. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase Ⅱ trial. Radiother Oncol,2012,102:4-9. [28]Wong SJ,Winter K,Meropol NJ,et al. Radiation therapy oncology group 0247: a randomized phase Ⅱ study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys,2012,82:1367-1375. [29]Rdel C,Liersch T,Becker H,et al.German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol,2012,13:679-687. [30]Aschele C,Cionini L,Lonardi S,et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized Phase Ⅲ trial. J Clin Oncol,2011,29:2773-2780. [31]Gérard JP,Azria D,Gourgou-Bourgade S,et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the Phase Ⅲ trial ACCORD 12/0405-Prodige 2. J Clin Oncol,2010,28:1638-1644. [32]Rodel C,Arnold D,Hipp M,et al. Phase Ⅰ-Ⅱ trial of cetuximab,capecitabine,oxaliplatin,and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys,2008,70:1081-1086. [33]Horisberger K,Treschl A,Mai S,et al. Cetuximab in combination with capecitabine,irinotecan,and radiotherapy for patients with locally advanced rectal cancer: results of a Phase Ⅱ MARGIT trial. Int J Radiat Oncol Biol Phys,2009,74:1487-1493. [34]Kim SY,Hong YS,Kim DY,et al. Preoperative chemoradiation with cetuximab,irinotecan,and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase Ⅱ study. Int J Radiat Oncol Biol Phys,2011,81:677-683. [35]Crane CH,Eng C,Feig BW,et al. Phase Ⅱ trial of neoadjuvant bevacizumab,capecitabine,and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys,2010,76:824-830. [36]Kennecke H,Berry S,Wong R,et al. Preoperative bevacizumab,capecitabine,oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase Ⅱ trial. Eur J Cancer,2012,48:37-45. [37]Resch G,De Vries A,Ofner D,et al. Preoperative treatment with capecitabine,bevacizumab and radiotherapy for primary locally advanced rectal cancer-a two stage phase Ⅱ clinical trial. Radiother Oncol,2012,102:10-13.
2013, Vol. 22 
